Loading...
  • doses
  • The vaccine is administered by intramuscular injection, and the recommended schedule is a 3-dose series with the second and third doses administered 2 and 6 months after the first dose. (cdc.gov)
  • Main outcome measures Vaccine efficacy against cervical, vulvar, and vaginal intraepithelial neoplasia grade I and condyloma in a per protocol susceptible population that included subjects who received all three vaccine doses, tested negative for the relevant vaccine HPV types at day 1 and remained negative through month 7, and had no major protocol violations. (bmj.com)
  • All 3 doses of the vaccine should be given within 6 months. (kramesonline.com)
  • The rate of confirmed GBS within 42 days of vaccination was 0.36 cases per million vaccine doses, which was less than the published background rate in the general population of persons aged 11 to 18 years. (chop.edu)
  • The goals of such trials may include reducing the number of doses of a current vaccine, evaluating a vaccine similar to a licensed vaccine, increasing the valency of a licensed vaccine by including VLPs for additional HPV types, or evaluating alternative prophylactic vaccines that also use a viral capsid protein or polypeptide to induce neutralizing antibodies. (nih.gov)
  • The Working Group recommended that immunological non-inferiority is an appropriate end-point in such situations, independent of the number of vaccine doses used to demonstrate such non-inferiority, with reduction in disease being verified by post-licensure monitoring. (nih.gov)
  • Two doses of the measles, mumps and rubella, or MMR, vaccine are now recommended for unvaccinated health care workers who were born before 1957 during an outbreak of measles or mumps. (aafp.org)
  • oncogenic
  • 9 These self-collected specimens can then be used to screen for the presence of human papillomavirus types of high oncogenic risk (herein referred to as high-risk HPV), and women whose test results are positive for high-risk HPV can then be encouraged to seek further testing (e.g. (cmaj.ca)
  • adverse
  • As a consequence, an epidemiological assessment of the vaccine adverse event reporting system database was undertaken for adverse event reports associated with vaccines administered from 2006 to 2014 to 6-39 year-old recipients with a listed US residence and a specified female gender. (sanevax.org)
  • Food and Drug Administration licensing analysis 11 12 of safety trials reports most adverse events occur in girls naïve to the four vaccine HPV types prior to vaccination. (bmj.com)
  • Girls seronegative and PCR negative to types 6, 11, 16 and 18 at baseline record the highest incidence of systemic adverse events, the highest proportion of 'moderate to severe' systemic adverse events and the highest incidence of headache compared with women who evidenced prior exposure to vaccine HPV types at baseline. (bmj.com)
  • Adverse Effects of Vaccines: Evidence and Causality. (vaccinesafety.edu)
  • Inactivated influenza vaccine during pregnancy and risks for adverse obstetric events. (vaccinesafety.edu)
  • vaginal
  • Vaccine efficacy against any lesion (regardless of HPV type) in the generally naive population was 30% (17% to 41%), 75% (22% to 94%), and 48% (10% to 71%) for cervical, vulvar, and vaginal intraepithelial neoplasia grade I, respectively, and 83% (74% to 89%) for condyloma. (bmj.com)
  • In trials conducted in >17,500 young adult women, such a vaccine was 95%-100% effective in preventing cervical, vaginal, and vulvar neoplasias and anogenital condylomata related to HPV-6, -11, -16, and -18 in women naive for the respective HPV vaccine types at enrollment [8- (natap.org)
  • influenza
  • Participants who have received standard of care (e.g., hepatitis B, influenza, and tetanus) vaccines are not excluded. (knowcancer.com)
  • The notion that Guillain-Barre syndrome (GBS) could be a consequence of vaccination was born of the swine influenza vaccine program administered in the United States in 1976. (chop.edu)
  • Since that time, the relationship between influenza vaccine and GBS has been variable. (chop.edu)
  • Therefore, one could reasonably argue that influenza vaccine prevents GBS. (chop.edu)
  • They found the receipt of any influenza vaccine (seasonal or pandemic) increased the risk of GBS by 1.4 (relative risk = 1.41). (chop.edu)
  • The authors investigated the relative risk of GBS among 45 million people immunized with the influenza A (H1N1) 2009 monovalent vaccine. (chop.edu)
  • The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices' 2010 recommended adult, adolescent and childhood immunization schedules include new options for the human papillomavirus vaccination in adults as well as the addition of the H1N1 influenza vaccination among those suggested for children. (aafp.org)
  • New recommendations for flu vaccinations include the influenza A (H1N1) 2009 monovalent vaccine. (aafp.org)
  • safety
  • Cochrane 2 confirms the limitations of using vaccine components as controls, since these components may be important to safety analysis. (bmj.com)
  • Vaccine Safety ● Do Vaccines Cause Diabetes? (vaccinesafety.edu)
  • For HPV, the most frequent reasons included those for the other vaccines as well as 4 others, including "Not sexually active" and "Safety concerns/Side effects. (aappublications.org)
  • The reasons for vaccine refusal for human papillomavirus vaccine differ from other teen vaccines, and concerns about its safety are increasing over time. (aappublications.org)
  • 15 , 16 A recent study in infants indicated that parents who delayed or refused vaccines were more likely to have vaccine safety concerns and to perceive fewer benefits associated with vaccines. (aappublications.org)
  • We hypothesized that prior exposure to opinions rejecting the safety or value of HPV vaccines would be associated with an increased risk of posting similar opinions and tested this hypothesis by analyzing temporal sequences of messages posted on Twitter (tweets). (jmir.org)
  • investigational
  • Use of any systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids, investigational vaccines, interleukins, interferons, growth factors, or intravenous immunoglobulin (IVIG) within 45 days prior to study entry. (knowcancer.com)